Dyax Recognized As A “Top Place To Work” By The Boston Globe For Second Year In A Row
BURLINGTON, Mass.--(BUSINESS WIRE)--Dyax Corp. (NASDAQ: DYAX), a biopharmaceutical company focused on the development and commercialization of novel biotherapeutics for unmet medical needs, today announced that it has been named one of the Top Places to Work in Massachusetts by The Boston Globe for the second year in a row.
“At Dyax, we understand the importance of cultivating a positive atmosphere and hope to continue to inspire our team members in all of their professional endeavors. I extend my sincere thanks to all the employees of Dyax for their hard work and dedication.”
“We are honored to be recognized again by The Boston Globe as one of the top places to work,” said Gustav Christensen, President and Chief Executive Officer of Dyax. “At Dyax, we understand the importance of cultivating a positive atmosphere and hope to continue to inspire our team members in all of their professional endeavors. I extend my sincere thanks to all the employees of Dyax for their hard work and dedication.”
The Boston Globe Top Places to Work 2015 magazine was published in The Boston Sunday Globe on November 15 and will also be featured on BostonGlobe.com/topplaces. Dyax ranked 2nd out of all Medium-sized Massachusetts employers, defined as companies with 100-249 employees.
The rankings in the Top Places to Work are based on confidential survey information collected by Workplace Dynamics, an independent company specializing in employee engagement and retention, from nearly 77,000 individuals at 357 Massachusetts organizations.
Dyax is a biopharmaceutical company focused on the development and commercialization of novel biotherapeutics for unmet medical needs. The Company is developing DX-2930, a fully human monoclonal antibody, for the prevention of HAE attacks. Additionally, Dyax markets KALBITOR® (ecallantide) for the treatment of acute attacks of HAE in patients 12 years of age and older.
Both DX-2930 and KALBITOR were identified using Dyax's proprietary phage display technology. Dyax has broadly licensed this technology under its Licensing and Funded Research Portfolio (LFRP). The current portfolio includes one FDA approved product, Eli Lilly and Company's CYRAMZA (ramucirumab), for which Dyax receives royalties, and multiple product candidates in various stages of clinical development for which the Company is eligible to receive future milestones and royalties.
For additional information about Dyax, please visit www.dyax.com.
For additional information about KALBITOR, including full prescribing information, please visit www.KALBITOR.com.
This press release contains forward-looking statements. Statements that are not historical facts are based on Dyax’s current expectations, beliefs, assumptions, estimates, forecasts and projections about the industry and markets in which Dyax operates. The statements contained in this release are not guarantees of future performance and involve certain risks, uncertainties and assumptions, which are difficult to predict. Therefore, actual outcomes and results may differ materially from what is expressed in such forward-looking statements because of risks, uncertainties and assumptions involved in any future projections. There are many factors that could cause actual results to differ from these forward-looking statements, including: risks and uncertainties relating to the clinical development of DX-2930; Dyax’s dependence on the expertise, effort, priorities and contractual obligations of third parties in the development of DX-2930 and in the marketing, sales and distribution of KALBITOR; competition from new and existing treatments for HAE; the uncertainty of patent and intellectual property protection relating to DX-2930, KALBITOR and the LFRP; Dyax's dependence on licensees and collaborators for development, clinical trials, manufacturing, sales and distribution of product candidates in the LFRP; uncertainties as to whether one or more product candidates in the LFRP will achieve development and regulatory milestones and be commercialized and generate royalties; uncertainties regarding Lilly's ability to successfully market CYRAMZA for the treatment of advanced gastric cancer; and other risk factors described or referred to in Item 1A, “Risk Factors” in Dyax’s most recent Annual Report on Form 10-K and other periodic reports filed with the Securities and Exchange Commission. Dyax cautions investors not to place undue reliance on the forward-looking statements contained in this release. These statements speak only as of the date of this release, and Dyax undertakes no obligations to update or revise these statements, except as may be required by law.
Dyax, the Dyax logo and KALBITOR are registered trademarks of Dyax Corp.
CYRAMZA is a trademark owned by or licensed to Eli Lilly and Company, its subsidiaries, or affiliates.
Jennifer Robinson, 617-250-5741
Director, Investor Relations and Corporate Communications